2001 (7) TMI 531

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... hankar, Member (T)]. ICPA Health Products Pvt. Ltd., the appellant was at the relevant time engaged in the manufacture of erythromycin stearate as a loan licensee for Abott Laboratories Ltd. The process of manufacture that was involved was conversion of thiocyanate into erythromycin base, which is reacted with stearic acid in order to obtain erythromycin stearate. Abott Laboratories import .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... ent of duty. 2. The objection issued to the appellant was that in the light of these transactions which we have narrated, it was not permissible for Abott Laboratories to receive under Rule 57F(2) the same thiocyanate which it had cleared under Rule 57F(1). Therefore it was not permissible for the appellant to take credit of the duty paid by Abott Laboratories on thiocyanate. The notice proposed .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... romycin stearate had been cleared by Abott to the appellant, credit that would have been taken would be 5%. In that case, Abott would have been entitled to the credit at 15% of thiocyanate. There is thus no loss to government. That however is not material. What is material is that however strange or unusual the conduct of the parties, they have acted within the rules. There is no prohibition in th .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X